The global chemiluminescence immunoassay market was valued at USD 12.59 billion in 2025 and is estimated to reach USD 13.18 billion in 2026. The market is further anticipated to grow to USD 19.02 billion by 2034, registering a compound annual growth rate (CAGR) of 4.69% during the forecast period from 2026 to 2034.
The chemiluminescence immunoassay market is expected to witness robust growth in 2026 due to the increasing demand for highly sensitive and accurate diagnostic technologies across healthcare facilities worldwide. Chemiluminescence immunoassay is an advanced diagnostic technique that combines chemiluminescent detection with immunochemical reactions to identify and quantify specific analytes in biological samples. The chemiluminescence immunoassay market is gaining significant momentum owing to the rising prevalence of chronic and infectious diseases, increasing demand for early disease detection, and growing adoption of automated diagnostic systems. Healthcare providers are increasingly utilizing chemiluminescence immunoassay platforms for diagnosing endocrine disorders, infectious diseases, cardiovascular conditions, and oncology-related indications because of their high sensitivity, specificity, and rapid turnaround time. Furthermore, the increasing emphasis on precision medicine and personalized treatment approaches is positively influencing the expansion of the chemiluminescence immunoassay market. Continuous technological advancements in laboratory automation and increasing investments in healthcare infrastructure are expected to further accelerate the growth of the chemiluminescence immunoassay market during 2026.
Continue reading for more details:
https://www.fortunebusinessinsights.com/chemiluminescence-immunoassay-market-112515
The chemiluminescence immunoassay market is segmented based on product, application, end user, and geography. By product, the market is categorized into analyzers, reagents and consumables, and software and services. Among these segments, reagents and consumables account for a substantial share of the chemiluminescence immunoassay market owing to their repeated use in diagnostic testing procedures and increasing test volumes across clinical laboratories and hospitals. The analyzers segment is also witnessing considerable growth due to rising adoption of automated diagnostic instruments that improve laboratory efficiency and testing accuracy.
Based on application, the chemiluminescence immunoassay market is divided into infectious diseases, oncology, endocrinology, cardiovascular disorders, autoimmune diseases, and other clinical applications. Infectious disease testing represents a significant market segment due to increasing incidences of viral and bacterial infections and growing demand for rapid diagnostic procedures. Endocrinology and oncology applications are also experiencing substantial growth because chemiluminescence immunoassay technologies provide highly accurate detection of hormonal disorders and cancer biomarkers.
By end user, the chemiluminescence immunoassay market includes hospitals, clinical laboratories, diagnostic centers, pharmaceutical and biotechnology companies, and academic and research institutes. Hospitals and clinical laboratories dominate the market due to rising patient volumes and increasing demand for advanced diagnostic solutions capable of delivering rapid and reliable test results.